US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Friday that the Phase 3 TroFuse-015 trial evaluating investigational drug sacituzumab tirumotecan (sac-TMT) met its primary endpoint of overall survival (OS) in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least two previous lines of systemic therapy.
The trial demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with treatment of physician's choice, making sac-TMT the first TROP2-directed antibody-drug conjugate (ADC) to demonstrate an overall survival benefit in this patient population in a global Phase 3 study.
However, the trial did not meet the secondary endpoint of progression-free survival assessed by blinded independent central review. Objective response rates showed a nominal improvement in favour of sac-TMT, and the safety profile remained consistent with previous studies, with no new safety signals identified.
Merck plans to present the findings at an upcoming medical meeting and share the data with regulatory authorities. TroFuse-015 represents the second positive Phase 3 readout from the company's TroFuse development programme, which comprises 18 ongoing global Phase 3 trials evaluating sac-TMT across multiple cancer types and treatment settings.
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Ichnos Glenmark Innovation submits IND for ISB 2301 to treat solid tumours
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Onward Therapeutics closes Series B financing
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Apotex launches generic version of INLYTA in US market
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications